<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04908306</url>
  </required_header>
  <id_info>
    <org_study_id>2011308-01</org_study_id>
    <nct_id>NCT04908306</nct_id>
  </id_info>
  <brief_title>IMAGE-HF: Project IIa Canadian CArdiomyopathy Registry for Device Therapy</brief_title>
  <acronym>CanCARD-MR</acronym>
  <official_title>IMAGE-HF: Project IIa - Canadian CArdiomyopathy Registry for Device Therapy (CanCARD-MR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ottawa Heart Institute Research Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ottawa Heart Institute Research Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Delayed enhanced MRI in patients (of either ischemic or non-ischemic cause) being referred&#xD;
      for primary prevention ICD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Device therapy using defibrillators and cardiac resynchronization therapy (CRT) is an&#xD;
      important advance in the care of patients with acquired heart disease and heart failure. In&#xD;
      specific groups these devices appear to significantly reduce the risk of sudden cardiac death&#xD;
      and progression of heart failure. However, our ability to identify ideal candidates, and&#xD;
      those who are most likely to respond and benefit from this therapy, is poor.&#xD;
&#xD;
      Preliminary studies using specialized Magnetic Resonance Imaging (MRI) appears to be one of&#xD;
      the more valuable ways of predicting response to device therapy and holds substantial promise&#xD;
      for patients with cardiomyopathy.&#xD;
&#xD;
      Large, prospective registries are necessary to explore its real-world utility for risk&#xD;
      prediction across a broad spectrum of patients. Can-CARD MR is a national, multi-centre&#xD;
      registry designed to address this particular need.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 11, 2011</start_date>
  <completion_date type="Anticipated">August 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Occurrence of a)appropriate ICD therapy (shock or anti-tachycardia pacing (ATP)) or sudden cardiac death</measure>
    <time_frame>1 year</time_frame>
    <description>Occurrence of a)appropriate ICD therapy (shock or anti-tachycardia pacing (ATP)) or sudden cardiac death</description>
  </primary_outcome>
  <enrollment type="Actual">502</enrollment>
  <condition>Heart Failure</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients referred for or being considered for primary prevention ICD, with or without CRT,&#xD;
        will be recruited from the Electrophysiology services at each enrolling site&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  .Any patient accepted for primary prevention ICD (+/-) CRT)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known contra-indications to MRI.&#xD;
&#xD;
          -  Recent myocardial infarction or revascularization procedure within the past 3 months.&#xD;
&#xD;
          -  GFR (glomerular filtration rate) â‰¤ 30 ml. / min/ m2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>David Birnie</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ottawa Heart Institute Research Corporation</affiliation>
  </overall_official>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

